Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin ‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway.

In conclusion, combination treatment with motesanib and cisplatin revealed a synergistically enhanced anticancer effect on cisplatin‑resistant human bladder cancer cells, accompanied with induced apoptosis and cell cycle arrest. Thus, the multikinase inhibitor motesanib could be developed as possible therapeutic agent for bladder cancer. PMID: 30816494 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30816494?dopt=Abstract

Source: Oncology Reports - March 4, 2019 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research